Abstract:Keval Yerigeri, 1 Saurav Kadatane, 2 Kai Mongan, 3 Olivia Boyer, 4 Linda LG Burke, 5 Sidharth Kumar Sethi, 6 Christoph Licht, 7 Rupesh Raina 8 1 Department of Internal Medicine-Pediatrics, Case Western Reserve University/The MetroHealth System, Cleveland, OH, USA; 2 Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; 3 Northeast Ohio Medical University, Rootstown, OH, USA; 4 Department of Pediatric Nephrology, Dialysis and Transplantation, Necker-Enfants Malades Hospital, MARHEA reference Center, Imagine Institute, Paris Cité University, Paris, France; 5 aHUS Global Advocate with aHUS Alliance, Cape Elizabeth, ME, USA; 6 Department of Pediatric Nephrology and Pediatric Renal Transplant Medicine, Kidney and Urology Institute, Medanta, The Medicity, Gurgaon, Haryana, India; 7 Department of Paediatrics, Division of Nephrology, University of Toronto, Toronto, ON, Canada; 8 Division of Pediatric Nephrology, Akron Children's Hospital, Akron, OH, USA Correspondence: Rupesh Raina, Tel +1 216 401 7894, Email Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy (TMA) defined by the triad of hemolytic anemia, thrombocytopenia, and acute kidney injury. Microthrombi develop in the glomerular capillaries secondary to endothelial damage and exert shear stress on red blood cells, consume platelets, and contribute to renal dysfunction and failure. Per current understanding of pathophysiology, HUS is classified into infectious, secondary, and atypical disease. The most common etiology is infectious sequelae of Shiga toxin-producing Escherichia coli (STEC); other causative organisms include shigella and salmonella. Secondary HUS arises from cancer, chemotherapy, solid organ and hematopoietic stem cell transplant, pregnancy, or autoimmune disorders. Primary atypical hemolytic-uremic syndrome (aHUS) is associated with genetic mutations in complement and complement regulatory proteins. Under physiologic conditions, complement regulators keep the alternative complement system continuously active at low levels. In times of inflammation, mutations in complement-related proteins lead to uncontrolled complement activity. The hyperactive inflammatory state leads to glomerular endothelial damage, activation of the coagulation cascade, and TMA findings. Atypical hemolytic-uremic syndrome is a rare disorder with a prevalence of 2.21 to 9.4 per million people aged 20 years or younger; children between the ages of 0 and 4 are most affected. Multidisciplinary health care is necessary for timely management of its extra-renal manifestations. These include vascular disease of the heart, brain, and skin, pulmonary hypertension and hemorrhage, and pregnancy complications. Adequate screening is required to monitor for sequelae. First-line treatment is the monoclonal antibody eculizumab, but several organ systems may require specialized interventions and coordination of care with sub-specialists. Keywords: atypical hemolytic uremic syndrome, eculizumab, plasma exchange, complications, extra-renal manifestations Thrombotic microangiopathies (TMA) are a constellation of disorders characterized by injury to the endothelium of micro-vessels, resulting sequentially in platelet activation, micro-thrombosis, Coombs-negative hemolytic anemia, and thrombocytopenia. 1,2 The differential for TMA disorders is demonstrated in Figure 1. The development of microthrombi can lead to small vessel occlusion, downstream ischemia, and end-organ damage. TMA encompasses thrombotic thrombocytopenic purpura (TTP), hemolytic-uremic syndrome (HUS), and atypical hemolytic-uremic syndrome (aHUS). The overlap between these conditions makes a definitive diagnosis challenging and demands extensive work-up. 3 Figure 1 The differential diagnosis for thrombotic microangiopathies (TMAs) is broad and includes infection-associated hemolytic uremic syndrome (HUS), atypical hemolytic-uremic syndrome (aHUS), and thrombotic thrombocytopenic purpura (TTP). The most common infectious source of HUS is Shiga-toxin producing Escherichia coli (STEC). Activity of the ADAMTS13 enzyme is a key diagnostic variable. The goals of this review are to provide an update on the genetic mechanisms behind complement dysfunction in aHUS, detail organ-specific clinical manifestations, and outline current management strategies. Multi-organ disease involvement belies the need for a multidisciplinary approach to management. The complement system has three pathways: classical, alternative, and lectin-binding. These pathways have different initial steps but converge on forming C3 convertase to propagate complement activity and destroy path -Abstract Truncated-

An international consensus approach to the management of atypical hemolytic uremic syndrome in children

Outcomes from the International Society of Nephrology Haemolytic Uraemic Syndromes International Forum

Clinical Characteristics and Outcome of Canadian Patients Diagnosed With Atypical Hemolytic Uremic Syndrome

Management of pediatric hemolytic uremic syndrome

Eculizumab as first-line treatment for patients with severe presentation of complement factor H antibody-mediated hemolytic uremic syndrome

Outcome of atypical hemolytic uremic syndrome: role of triggers and complement abnormalities in the response to C5 inhibition

Modern Approaches to the Management of Children with Atypical Hemolytic Uremic Syndrome

Pharmacological Management of Atypical Hemolytic Uremic Syndrome in Pediatric Patients: Current and Future

Hemolytic uremic syndrome in a developing country: Consensus guidelines

Hemolytic-uremic syndrome: 24 years' experience of a pediatric nephrology unit

Typical or Atypical Hemolytic Uremic Syndrome and the Use of Eculizumab: 4 Illustrative Cases

Anti-CFH-associated hemolytic uremic syndrome: do we still need plasma exchange?

Treatment discontinuation in adults with atypical hemolytic uremic syndrome (aHUS): a qualitative study of international experts' perspectives with associated cost-consequence analysis

Pediatric atypical hemolytic–uremic syndrome due to auto-antibodies against factor H: is there an interest to combine eculizumab and mycophenolate mofetil?

Atypical Hemolytic-Uremic Syndrome: Genetic Basis, Clinical Manifestations, and a Multidisciplinary Approach to Management

Systemic lupus erythematosus presenting with atypical hemolytic uremic syndrome: a case report and review of the literature

Haemolytic Uremic Syndrome: A Study Cohort over 10-Year Period in a Paediatric Tertiary Centre Hospital

Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS

Clinical and Genetic Characteristics of Atypical Hemolytic Uremic Syndrome in Children: A Chinese Cohort Study

Molecular pharmacology in complement-mediated hemolytic disorders

Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Resistant to Plasma Exchange/Infusion (PE/PI): Results of An Extension Study